← board
GDTC
CytoMed Therapeutics Pte Ltddistress 4/10 · elevated risk$0.83-13%today-69% from 52w high
Oncology 1
Lead: Cancer
Revenue
pre-revenue
Liquidity
$2M
Runway
0.6 yrs
Shares 1y
0%
Price & events
-12.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-13.5%
1D
-18.6%
1W
-17.8%
1M
-17.8%
3M
-16.9%
6M
-56.1%
1Y
-59.5%
2Y
—
5Y
-79.2%
All
Overview
- Market Cap
- $9.82M
- Enterprise Value
- $8.10M
- Volume
- 5.80K
- 52 Week Range
- $0.72 – $2.69
- Total Shares
- 11.83M
- Float Shares
- 3.69M
- Short %
- 1.08%
- % Held by Insiders
- 68.78%
- % Held by Institutions
- 0.18%
- RVOL
- 0.46x
- Beta
- 0.02
Pipeline stages · 1 programs
Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-11 | Phase 1 | Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) | Cancer, Malignancy, Refractory Cancer, Relapsed Cancer | 12 | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-10-10BenchmarkSpeculative Buy
Competitors — Cancer
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- AMGNAMGEN INC$195.4B · D3
- PFEPFIZER INC$142.2B · D3
- BNTXBioNTech SE$23.1B · D1
- OLMAOlema Pharmaceuticals, Inc.$990M · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-06-23CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D - Stock Titan
- 2026-06-15CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market - Stock Titan
- 2026-03-02Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.